Drug
Single Ft1050 Treated Ucb Unit
Single Ft1050 Treated Ucb Unit: highest development phase Phase 1, developed by Fate Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Fate Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Single FT1050 treated UCB unit NCT01527838 | Phase 1 | Non-Hodgkin's Lymphoma (NHL) |
Latest
No recent events.
Follow Single Ft1050 Treated Ucb Unit on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.